Abstract:Background: Nonalcoholic fatty liver disease (NAFLD) has become a growing public health problem worldwide. However, there is still lack of effective treatment strategies except lifestyle intervention. Objectives: To evaluate whether quercetin improves intrahepatic lipid content in patients with NAFLD. Methods: In this randomized, double-blind, placebo-controlled crossover trial, 41 patients with NAFLD were randomly assigned to receive the quercetin (500 mg) or placebo capsules for 12 wk, then switched interventions for another 12 wk after a 4-wk washout period. The primary outcome was intrahepatic lipid content evaluated by magnetic resonance imaging estimated proton density fat fraction. The secondary outcomes were liver function measurements, etc. Safety outcomes included blood routine. Results: A total of 36 patients completed the trial. In intention-to-treat analyses, the quercetin intervention moderately decreased the intrahepatic lipid contents from 11.5% ± 6.4% to 9.6% ± 5.8%, compared with the placebo intervention (decreased by 0.1% ± 2.6%, P = 0.013 and adjusted P value is 0.028). Body weight and body mass index were mildly reduced by 1.5 ± 2.6 kg and 0.5 ± 0.9 kg/m2 after the quercetin intervention (P < 0.05 and both adjusted P values are 0.038), whereas the reductions were only 0.2 ± 1.8 kg and 0.1 ± 0.7 kg/m2 after the placebo intervention. The intrahepatic lipid content reductions were noticeably positively associated with the body weight losses after the quercetin and placebo interventions (r = 0.557 and 0.412, P < 0.001 and P = 0.007, respectively). Subgroup analyses found that the reduction of intrahepatic lipid contents in females (3.0% ± 3.7%) was about twice as large as that in males (1.4% ± 2.5%) with a trend of statistical significance (P = 0.113 and adjusted P value is 0.061). There were no significant differences in other secondary and safety outcomes. No adverse events associated with study intervention were found. Conclusions: Twelve weeks treatment of quercetin could reduce intrahepatic lipid contents in patients with NAFLD, possibly explained by a slightly larger body weight loss in the quercetin group. Trial registration: The trial is registered at www.chictr.org.cn as ChiCTR2100047904.

Isorhamnetin in Quinoa Whole-Grain Flavonoids Intervenes in Non-Alcoholic Fatty Liver Disease by Modulating Bile Acid Metabolism through Regulation of FXR Expression

Isolation and purification of flavonoids from quinoa whole grain and its inhibitory effect on lipid accumulation in nonalcoholic fatty liver disease by inhibiting the expression of CD36 and FASN

Huatan Qushi Formula Alleviates Non-Alcoholic Fatty Liver Disease Via PI3K/Akt Signaling and Gut Microbiota Modulation

Quercetin Ameliorates HFD-induced NAFLD by Promoting Hepatic VLDL Assembly and Lipophagy Via the IRE1a/XBP1s Pathway.

Quinoa Polyphenol Extract Alleviates Non-Alcoholic Fatty Liver Disease via Inhibiting Lipid Accumulation, Inflammation and Oxidative Stress

Dietary Isoquercetin Reduces Hepatic Cholesterol and Triglyceride in NAFLD Mice by Modulating Bile Acid Metabolism via Intestinal FXR-FGF15 Signaling

Alleviating the Effect of Quinoa and the Underlying Mechanism on Hepatic Steatosis in High-Fat Diet-Fed Rats

Quercetin and non-alcoholic fatty liver disease: A review based on experimental data and bioinformatic analysis

Quinoa Ameliorates Hepatic Steatosis, Oxidative Stress, Inflammation and Regulates the Gut Microbiota in Nonalcoholic Fatty Liver Disease Rats

Isoliquiritigenin attenuates non-alcoholic fatty liver disease via the amelioration of hepatic inflammation and autophagy in mice

Novel insights into the role of quercetin and kaempferol from Carthamus tinctorius L. in the management of nonalcoholic fatty liver disease via NR1H4-mediated pathways

Qinlian Hongqu Decoction Modulates FXR/TGR5/GLP-1 Pathway to Improve Insulin Resistance in NAFLD Mice: Bioinformatics and Experimental Study

Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model.

Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial

Inulin Alleviates HFD-induced NAFLD by Hepatic Macrophage Polarization and Lipid Metabolism Via Gut-Liver Axis

Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice

Metabolomics Characterizes The Effects And Mechanisms Of Quercetin In Nonalcoholic Fatty Liver Disease Development

Isorhamnetin: A Hepatoprotective Flavonoid Inhibits Apoptosis and Autophagy Via P38/PPAR-α Pathway in Mice.

A-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARa Pathway

The Isoxazole Based Flavonoid Derivative 1 Ameliorates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice by Regulating Lipid Metabolism and Inflammatory Responses

Amelioration of free fatty acid‐induced fatty liver by quercetin‐3‐O‐β‐D‐glucuronide through modulation of peroxisome proliferator‐activated receptor‐alpha/sterol regulatory element‐binding protein‐1c signaling